Caspofungin: Clinical Trials

12 trials of Caspofungin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 unknown, 1 not yet recruiting, 1 terminated. 12 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 412Completed 7, Unknown 3, Not yet recruiting 1, Terminated 1

Follow Caspofungin: new trials by email Literature Review of Caspofungin trials Research Report on Caspofungin

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial
Caspofungin only within the study, Caspofungin for 3 days within the study, Placebo only within the study - Candidemia, Invasive Candidiasis
Phase 4Not yet recruitingOliver Cornely, MD4202026-09-012026-09-01
To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation
Micafungin Sodium 50 MG Injection, Caspofungin Acetate - Liver Transplantation
Phase 4UnknownShanghai General Hospital, Shanghai Jiao Tong University School of Medicine2002022-10-012022-08-16
Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
caspofungin, TMP/SMZ(trimethoprim/sulfisoxazole), Methylprednisolone - Pneumocystis Pneumonia
Phase 4UnknownBin Du1222019-08-142019-09-12
Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study)
Echinocandins - Septic Shock, Peritonitis
Phase 4CompletedCentre Hospitalier Universitaire de Nīmes242017-01-282025-12-10
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
Itraconazole, Caspofungin - Hematologic Neoplasms
Phase 4TerminatedXian-Janssen Pharmaceutical Ltd.612016-11-302019-05-06
Optimal Dosage of Caspofungin in Critically Ill Patients
Caspofungin - Critically Ill, Suspected Invasive Candidiasis
Phase 4CompletedUniversity Medical Center Groningen202013-11-012015-10-30
Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
Caspofungin 70 mg - Bacterial Infections and Mycoses, Liver Disease
Phase 4CompletedErasme University Hospital202013-09-012019-02-15
Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
caspofungin - Invasive Pulmonary Aspergillosis, Chronic Obstructive Pulmonary Disease
Phase 4UnknownThe First Affiliated Hospital of Guangzhou Medical University402012-01-012014-01-23
Effect of Weight and/or Obesity on Caspofungin Drug Concentrations
Caspofungin - Obesity, Fungal Infection
Phase 4CompletedTexas Tech University Health Sciences Center182010-02-012017-02-10
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
micafungin, Micafungin, Caspofungin - Candidemia
Phase 4CompletedGary E. Stein, Pharm.D.212008-12-012024-04-30
Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Caspofungin, Normal Saline - Invasive Candidiasis
Phase 4CompletedMycoses Study Group2222007-08-012011-05-09
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
Ambisome, caspofungin - Invasive Aspergillosis
Phase 4CompletedGilead Sciences302004-03-012015-07-09

Conditions studied

Candidemia (2)  ·  Candidiasis, Invasive (2)  ·  Bacterial Infections and Mycoses (1)  ·  Critical Illness (1)  ·  Hematologic Neoplasms (1)  ·  Invasive Fungal Infections (1)  ·  Invasive Pulmonary Aspergillosis (1)  ·  Liver Diseases (1)  ·  Mycoses (1)  ·  Obesity (1)  ·  Peritonitis (1)  ·  Pneumonia, Pneumocystis (1)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Shock, Septic (1)  ·  Torulopsis (1)

Sponsors

Bin Du (1)  ·  Centre Hospitalier Universitaire de Nīmes (1)  ·  Erasme University Hospital (1)  ·  Gary E. Stein, Pharm.D. (1)  ·  Gilead Sciences (1)  ·  Mycoses Study Group (1)  ·  Oliver Cornely, MD (1)  ·  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)  ·  Texas Tech University Health Sciences Center (1)  ·  The First Affiliated Hospital of Guangzhou Medical University (1)  ·  University Medical Center Groningen (1)  ·  Xian-Janssen Pharmaceutical Ltd. (1)

Countries

China (3)  ·  United States (3)  ·  France (2)  ·  Australia (1)  ·  Belgium (1)  ·  Germany (1)  ·  Netherlands (1)

Top investigators

Claire Roger, MD (1)  ·  Feng Ye, MD (1)  ·  Gary E Stein, Pharm.D. (1)  ·  Jan-Willem Alffenaar, PharmD, PhD (1)  ·  Lamine Mahi, MD (1)  ·  Luis Ostrosky-Zeichner, MD (1)  ·  Peter G Pappas, MD (1)  ·  Ronald Hall, PharmD, MSCS (1)

Results publications

PMID 23459494, PMID 24550378, PMID 27855112, PMID 29860319, PMID 33846133

NIH funding

2016 (1), 5UL1RR024982-02 (1)